Lexaria Bioscience Corp. announced on December 18, 2024, the creation of its new Scientific Advisory Board (SAB). The SAB is formed to assist in guiding Lexaria's rapid drug delivery platform technology and strategic development plans within the pharmaceutical industry.
The SAB will initially be comprised of four members, with Lexaria's President and Chief Scientific Officer, John Docherty, serving as its Chairman. This initiative aims to bring together external expertise to enhance the company's scientific direction.
The formation of the SAB is a strategic move to bolster Lexaria's research and development efforts. It is expected to provide valuable insights as the company continues to expand its DehydraTECH applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.